Translational in vivo models. Myth or reality?
It is very clear that the whole pharmaceutical industry has had significant and continuing problems in finding drugs which can effectively treat a wide range of diseases. Failures in Phase II and III, due to lack of efficacy, unwanted side effects and PK issues, continue to be very high. There is a high need for models which will allow an earlier and better prediction of the likely effect of a drug in a given disease. For many years, Taconic has been a major developer and supplier of translational in vivo rodent models to the pharmaceutical and academic community. We provide access to a wide range of transgenic in vivo models, either directly off-the-shelf, or via our custom model generation program. We have a very high degree of specialization in the production of humanized genetically modified mice, in which the mouse protein is replaced with an active human protein. In many cases these models have made significant contributions to drug discovery programs. Additionally we have a wide range of humanized tADMETT in vivo models, which enable a better prediction of the pharmacokinetic and safety behavior of a drug in humans. Our newly launched and developing tONCOT program allows investigators to better and more easily determine the efficacy of an prospective oncology drug. As well as the models described above, we are able, under a single company, to identify, generate, breed and analyze these models to provide our clients with the highest quality data. This has multiple advantages in terms of cost, timelines, logistics and data quality. We believe that the models we have and the services we supply around those can make a significant contribution to translational drug discovery, and will aid scientist's efforts to increase the success rate and efficiency of drug discovery programs. Read More...
|
